The documentary You Can See Everything, released on October 16, 2026, set a record as the highest-rated film on Letterboxd. The movie about Elizabeth Holmes also got near-perfect scores on Rotten Tomatoes and Metacritic. Many viewers showed great interest, though ratings could change as more people watch the film soon.

You Can See Everything documentary about Theranos founder Elizabeth Holmes is registering record ratings across film websites

Nathan Fielder and Lance Oppenheim's documentary You Can See Everything has apparently become the highest-rated feature film on Letterboxd after its theatrical release on October 16, 2026. The movie, which focuses on disgraced Theranos founder Elizabeth Holmes, has captivated the interest of cinephiles with its unsettling exploration of truth, deception, and performance. Its remarkable reception extends beyond Letterboxd, with near-perfect scores on Rotten Tomatoes and Metacritic. The documentary's early success has sparked discussions about its place in cinema history, although its ratings could change as more viewers watch it in the coming days.

You Can See Everything breaks Letterboxd rating records

You Can See Everything has generated amazing buzz among early watchers, with the average on Letterboxd being reported as 4.8 out of 5. If sustained, the rating would put the documentary ahead of several celebrated films that have long dominated discussions around the platform's highest-rated titles. These are the Japanese classic Harakiri, The Human Condition III: A Soldier's Prayer, 12 Angry Men and Come and See. Letterboxd's official Top 500 narrative-feature list, however, excludes documentaries, thus, the film's reported position does not necessarily translate into the same ranking on that chart.

This difference matters because Letterboxd ratings can evolve as more users view and rate a release. The enthusiasm of moviegoers who were already looking forward to seeing the film might also have helped early scores. But the reaction to Fielder and Oppenheim's idea has been extraordinary.

Rotten Tomatoes and Metacritic scores add to buzz

The documentary's reaction has extended over to other major review sites too. Deadline reports You Can See Everything has a 99 percent critics' rating on Rotten Tomatoes, with an audience score of 98 percent. Its critics' rating had been 100% previously, but fell once a negative review was submitted.

The movie has apparently scored 98 out of 100 on Metacritic, which puts it in the top-rated movies on the platform during the last few years. These scores are no guarantee of praise that will last, but rather a snapshot of its reception, but they do highlight the power of its early critical response.

The near-perfect ratings have also sparked conjecture about the film's awards possibilities, with speculation about whether it could prove to be a major candidate during the documentary awards season and beyond.

About You Can See Everything

The documentary is directed by Nathan Fielder, creator of Nathan for You, The Rehearsal and The Curse, and filmmaker Lance Oppenheim, director of Some Kind of Heaven. The 174-minute-long film chronicles the rise and fall of Elizabeth Holmes, founder of now-defunct health technology company Theranos.

Holmes invited a documentary team to follow her life just before she began a prison sentence for scamming investors. What started as an observational effort became a three-year project with filmmakers documenting Holmes and her partner, Billy Evans.

The film not only tells the traditional story about the Theranos crisis, but also interrogates the delicate link between truth, deception and performance. Its unorthodox technique has become fodder for discussion among viewers and critics alike, who debate what the footage says about Holmes and those trying to document her.

You Can See Everything release

Released theatrically on October 16, 2026, You Can See Everything is being distributed by A24, with its current theatrical rollout limited to the United States and Canada. Additional releases are scheduled in territories including Australia, Poland, Portugal, Serbia, the Czech Republic, Ireland and the United Kingdom. No Indian distribution has currently been announced.